ipharmacenter Consulting services

The UK government announced on December 1, 2025, an increase in the National Institute for Health and Care Excellence (NICE) thresholds used to evaluate new medicines' cost-effectiveness for the National Health Service (NHS). NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY This adjustment raises the standard range from £20,000 - £30,000 per quality-adjusted life year (QALY) gained to £25,000 - £35,000 per QALY, aiming to foster in

CMS has introduced the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a new 10‑year voluntary payment model in Original Medicare designed to expand technology‑supported care for people living with chronic diseases. The first performance period begins July 1, 2026, with applications due by April 1, 2026; applications submitted after that date will be considered for a January 1, 2027 start.​   What is the ACCESS Model? The ACCESS Model tests an outcom